Ligandrol 10mg/tab 60 Tabletten by Elbrus Pharmaceuticals

Usage

1. Establish your baseline before starting.: Measure body weight, record key compound-lift maxes, and if possible obtain a pre-cycle blood panel (total testosterone, LH, FSH) to give yourself a reference point for evaluating results and suppression.
2. Take one 10 mg tablet each morning.: Consistent daily timing maintains stable LGD-4033 plasma concentrations. Administration with a small meal may reduce any initial gastrointestinal sensitivity.
3. Maintain a structured caloric surplus.: Ligandrol amplifies the anabolic response to training and nutrition — a surplus of 300–500 kcal above TDEE, with protein intake at 1.8–2.2 g/kg bodyweight, is the recommended nutritional framework for a bulking cycle.
4. Track progressive overload week by week.: LGD-4033 supports accelerated strength adaptation; log each session's working weights to confirm that the compound's anabolic signal is being met with adequate training stimulus.
5. Monitor suppression signals from Week 4 onward.: Noticeable reductions in libido, morning erections, or energy levels are indicators that the hypothalamic-pituitary-testicular axis is being suppressed. This is expected but should be tracked.
6. Begin PCT immediately after the final tablet.: Given the 24–36 h half-life, the compound clears rapidly; initiate SERM-based PCT (Nolvadex 20–40 mg/day or Clomid 25–50 mg/day) on Day 1 post-cycle and run for four weeks to restore endogenous testosterone production.

Warnings

Frequently asked questions

How much lean mass can you realistically gain on LGD-4033 in an 8-week bulk?

Clinical Phase I data (Basaria et al., 2013) showed dose-dependent lean mass increases at doses as low as 1 mg/day; community-level bulking protocols using 10 mg/day commonly report 4–6 kg of lean mass over 8 weeks in a caloric surplus. Individual results depend on training load, calorie intake, and prior SARM experience. Gains at this dose are primarily lean tissue rather than water, making LGD-4033 one of the cleaner mass-building options among studied SARMs.

What is the standard LGD-4033 dosage protocol for bulking?

The most widely used bulking dose is 10 mg per day taken orally, once daily, for 6–10 weeks. Because LGD-4033 has a half-life of approximately 24–36 hours, a single morning dose maintains stable plasma concentrations throughout the day. Beginners sometimes start at 5 mg/day to assess tolerance before escalating to 10 mg. The 10 mg/tab format of this Elbrus product means no splitting is required at the standard dose.

How suppressive is Ligandrol LGD-4033 on natural testosterone levels?

LGD-4033 is the most suppressive of the well-characterised SARMs. Basaria et al. (2013) documented dose-dependent reductions in total testosterone and SHBG within 21 days at doses from 0.3–1 mg/day; at 10 mg/day, suppression is significant enough to require post-cycle therapy. LH and FSH are both reduced. Recovery typically occurs within 5 weeks post-cycle, but PCT with a SERM (e.g., Nolvadex or Clomid) is strongly recommended to restore the hypothalamic-pituitary-testicular axis efficiently.

Why is 10 mg/tab the most convenient tablet strength for LGD-4033?

10 mg per tablet matches the single most common clinical and community-documented efficacy threshold for LGD-4033, so one tablet per day covers the full standard dose without any splitting. Lower-strength tablets (e.g., 5 mg) require two tablets daily; higher-strength tabs create dosing inflexibility for those who want to titrate. The Elbrus 10 mg format simplifies cycle management and reduces user error in daily dosing.

Are the LGD-4033 tablets supplied in blister packs or a jar, and can they be split?

Elbrus Pharmaceuticals supplies these LGD-4033 tablets in a 60-count format. At 10 mg per tablet and a standard dose of one tablet daily, there is no practical need to split tablets during a normal bulking cycle. If a lower introductory dose of 5 mg is preferred, tablets can be halved with a pill cutter; the compressed-tablet format is mechanically suitable for splitting, though HPLC uniformity is validated for the whole tablet, not halves. (2) angle_used

Manufacturer

Where most discussion of Elbrus Pharmaceuticals' quality framework centres on testing methodology, the founding rationale behind the brand is worth stating plainly: Elbrus was established on the premise that the research-compound market had a structural credibility problem — not a manufacturing technology problem. Tablet compression, blister sealing, and GMP-grade facilities were widely available; what was absent was a transparent, batch-level analytical commitment that could be independently referenced rather than generically claimed. For the LGD-4033 product line, Elbrus resolved this by treating finished-product HPLC potency confirmation and LAL endotoxin screening as non-negotiable pre-distribution gates — not as optional quality additions layered onto a GMP certificate. The brand's position is that a GMP-compliant environment produces tablets with controlled processes, but only finished-product analytical release data demonstrates what is actually inside each tablet. This distinction, between process control and outcome verification, is the organising principle of Elbrus's QC architecture across its SARM product range. The company operates its oral tablet line within a documented ISO-aligned GMP environment, with environmental monitoring conducted on a per-shift basis. Lot traceability is maintained from API intake through compression, coating, and final packaging, creating an unbroken documentation chain that links the released product back to its verified source material.